Amniotic fluid stem cell-derived vesicles protect from VEGF-induced endothelial damage

Area of Science:

• Regenerative Medicine
• Nephrology
• Cell Biology

Background:

• Alport Syndrome causes progressive renal fibrosis and kidney dysfunction.
• Vascular Endothelial Growth Factor (VEGF) signaling is elevated in Alport Syndrome, leading to glomerular endothelial cell damage.
• The protective mechanisms of amniotic fluid stem cells (AFSC) in Alport Syndrome remain unclear.

Purpose of the Study:

• To investigate the role of extracellular vesicles (EVs) derived from AFSC in renoprotection against Alport Syndrome.
• To elucidate the mechanism by which AFSC-EVs modulate VEGF signaling in glomerular endothelial cells.

Main Methods:

• AFSC were injected into Alport Syndrome mouse models.
• Characterization of AFSC-derived EVs for surface markers including VEGFR1 and VEGFR2.
• Assessment of EVs' ability to modulate VEGF activity in glomerular endothelial cells.
• Evaluation of VEGFR1/sVEGFR1 knockout EVs in protection assays.

Main Results:

• AFSC-derived EVs exhibited exosomal and stem cell markers, including VEGFR1 and VEGFR2.
• EVs effectively trapped excess VEGF in glomerular endothelial cells via VEGFR1 binding, preventing cellular damage.
• EVs significantly modulated VEGF activity, mitigating glomerular damage in Alport mice.
• VEGFR1/sVEGFR1 knockout EVs failed to provide similar renoprotection, highlighting the importance of VEGF trapping.

Conclusions:

• Extracellular vesicles secreted by AFSC mediate renoprotection in Alport Syndrome by trapping excess VEGF.
• VEGF trapping by AFSC-EVs through VEGFR1 is a key mechanism for preventing glomerular endothelial cell damage.
• AFSC-derived EVs represent a promising glomerulus-specific targeted intervention for Alport Syndrome.